Development and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column

Attard, 2016, Prostate cancer, Lancet (London, England), 387, 70, 10.1016/S0140-6736(14)61947-4 Miyamoto, 2012, Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer, Cancer Discov., 2, 995, 10.1158/2159-8290.CD-12-0222 Deslypere, 1992, Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene, Mol. Cell. Endocrinol., 88, 15, 10.1016/0303-7207(92)90004-P Sharifi, 2005, Androgen deprivation therapy for prostate cancer, JAMA, 294, 238, 10.1001/jama.294.2.238 Scher, 2008, Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group, J. Clin. Oncol., 26, 1148, 10.1200/JCO.2007.12.4487 Scher, 2005, Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis, J. Clin. Oncol., 23, 8253, 10.1200/JCO.2005.03.4777 Sharifi, 2013, Minireview: androgen metabolism in castration-resistant prostate cancer, Mol. Endocrinol., 27, 708, 10.1210/me.2013-1007 Siegel, 2016, Cancer statistics 2016, CA Cancer J. Clin., 66, 7, 10.3322/caac.21332 Potter, 1995, Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-c17,20-lyase): potential agents for the treatment of prostatic cancer, J. Med. Chem., 38, 2463, 10.1021/jm00013a022 Jarman, 1998, The 16,17-double bond is needed for irreversible inhibition of human cytochrome p45017alpha by abiraterone (17-(3-pyridyl)androsta-5, 16-dien-3beta-ol) and related steroidal inhibitors, J. Med. Chem., 41, 5375, 10.1021/jm981017j Salvador, 2013, Steroidal 5alpha-reductase and 17alpha-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases, J. Steroid Biochem. Mol. Biol., 137, 199, 10.1016/j.jsbmb.2013.04.006 Garrido, 2014, A-ring modified steroidal azoles retaining similar potent and slowly reversible CYP17A1 inhibition as abiraterone, J. Steroid Biochem. Mol. Biol., 143, 1, 10.1016/j.jsbmb.2014.01.013 Grist, 2015, The development of abiraterone acetate for castration-resistant prostate cancer, Urol. Oncol., 33, 289, 10.1016/j.urolonc.2015.03.021 de Bono, 2011, Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med., 364, 1995, 10.1056/NEJMoa1014618 Ryan, 2013, Abiraterone in metastatic prostate cancer without previous chemotherapy, N. Engl. J. Med., 368, 138, 10.1056/NEJMoa1209096 Kluetz, 2013, Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary, Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 19, 6650, 10.1158/1078-0432.CCR-13-2134 Attard, 2012, Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer, J. Clin. Endocrinol. Metab., 97, 507, 10.1210/jc.2011-2189 Auchus, 2014, Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer, Oncologist, 19, 1231, 10.1634/theoncologist.2014-0167 Acharya, 2013, A phase I open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects, Xenobiotica Fate Foreign Comp. Biol. Syst., 43, 379, 10.3109/00498254.2012.721022 Li, 2015, Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer, Nature, 523, 347, 10.1038/nature14406 Li, 2016, Redirecting abiraterone metabolism to fine tune prostate cancer antiandrogen therapy, Nature, 10.1038/nature17954 U. Food and Drug Administration, Guidance for industry bioanalytical method validation, 2001.